Increasing epidemiological and experimental evidence implicates non-steroidal anti-in¯ammatory drugs (NSAIDs) as anti-tumorigenic agents. The precise mechanisms whereby NSAIDs exert their anti-neoplastic eects remain poorly understood. Studies from hereditary and sporadic colorectal cancer (CRC) patients suggest that NSAIDs may interfere with initiating steps of carcinogenesis, i.e. disturbances within the b-catenin signaling pathway. We therefore investigated b-catenin/ TCF signaling in response to aspirin or indomethacin, respectively, in four CRC cell lines (SW948, SW480, HCT116, LoVo). Both, aspirin and indomethacin inhibited transcription of a b-catenin/TCF-responsive reporter gene in a dose dependent manner. In addition, the b-catenin/TCF transcriptional target cyclin D1 was downregulated by both drugs. Endogenous b-catenin levels remained unaected by either drug. Moreover, indirect immuno¯uorescence studies revealed no signi®-cant changes of subcellular b-catenin localization in either cell line after NSAID treatment. Likewise, binding of the b-catenin/TCF complex to its speci®c DNAbinding sites was not altered, as demonstrated by electrophoretic mobility shift assay (EMSA) of nuclear extracts derived from NSAID treated cells. These results strongly suggest that aspirin and indomethacin attenuate the transcription of b-catenin/TCF-responsive genes, by modulating TCF activity without disrupting b-catenin/ TCF complex formation. Oncogene (2001) 20, 645 ± 653.
Introduction
The ®nding that human and animal tumor tissues contain increased levels of prostaglandins stimulated experimental and clinical research, demonstrating that NSAIDs can reduce tumor incidence (for review see Taketo, 1998a,b) . In several rodent models for colorectal cancer, the NSAIDs indomethacin, aspirin, sulindac and piroxicam were shown to reduce tumor growth. Results from sulindac-administration studies in FAP patients and epidemiological studies in patients treated with high doses of aspirin or other NSAIDs con®rmed the tumor suppressive eects (for review see DuBois and Smalley, 1996; Levy, 1997) .
Many of the therapeutic eects of NSAIDs are clearly due to inhibition of prostaglandin synthesis by inactivation of the cyclooxygenase 1 and 2 (COX-1 and COX-2) (Prescott and Fitzpatrick, 2000) . However, the importance of COX inhibition for the anti-proliferative eects by NSAIDs is controversial at present. The concentration of NSAIDs that are necessary for growth inhibition are 10 ± 100 times higher than that required to inhibit prostaglandin synthesis, suggesting the existence of additional cellular targets (Hanif et al., 1996; Ahnen, 1998) . A common mechanism of action seems to be induction of apoptosis, although several in vitro studies in CRC cells proposed that dierent molecular pathways are aected by distinct types of NSAIDs (Shi et al., 1995; Ricchi et al., 1997; Chan et al., 1998; Subbegowda and Frommel, 1998; RuÈ scho et al., 1998; Pattern and DeLong, 1999; Smith et al., 2000) . Little is known about COX independent molecular targets of NSAIDs in cancer cells. Sulindac sul®de, the major metabolite of the prodrug sulindac was shown to inhibit Ras signaling by blocking the interaction of p21ras with its major downstream target Raf kinase (Herrmann et al., 1998) . Salicylates such as aspirin were described to inhibit the NF-kB pathway by interaction with IkB kinase-b (IKK-b) (Kopp and Ghosh, 1994; Yin et al., 1998) . In this study, we focused on a signaling pathway involved in initiation of colorectal cancer, since NSAIDs were reported to prevent or slow down tumorigenesis rather than to reduce the growth of advanced carcinomas.
Virtually all colonic carcinomas arise within preexisting adenomas or areas of dysplasia. The pathways that regulate and coordinate growth, dierentiation, and apoptosis of epithelial cells in the colonic mucosa have been extensively studied (for review see . Accumulating evidence indicates that the bcatenin/TCF signaling pathway plays a key role in regulation of these mechanisms. Mutations in the APC or b-catenin gene which encode components of the bcatenin/TCF-pathway initiate the development of almost all human colon cancers. Wild-type APC in complex with axin and glycogensynthase kinase 3b (GSK 3b) targets b-catenin for degradation, thereby maintaining low levels of b-catenin in normal cells (reviewed in Polakis et al,. 1999 ). In colorectal tumor (Behrens et al., 1996; Pennisi, 1998) , i.e. c-myc (He et al., 1998) and cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 1999) , which might be involved in tumorigenesis.
In the present study, we addressed the eects of the anti-in¯ammatory drugs aspirin, and indomethacin on b-catenin signaling mechanisms in CRC cells. We present evidence that the transcriptional activity of the b-catenin/TCF complex is strongly inhibited by these NSAIDs without aecting the total amount of bcatenin and/or TCF-4.
Results

Down-regulation of b-catenin/TCF-activity by aspirin and indomethacin
To examine TCF activity in CRC cell lines we used reporter gene constructs containing three copies of an either optimized or mutant TCF-binding element, respectively, upstream of a minimal c-fos promoter, driving the luciferase gene . Aspirin and indomethacin had no eect on the c-fos promoter alone, which was determined by analysing cfos expression using a semiquantitative RT ± PCR assay (data not shown).
SW948 cells, which show an elevated level of catenin/TCF mediated transcription due to an inactivating APC mutation (Dihlmann et al., 1999) were transfected with the reporter constructs and subsequently treated with NSAIDs. Figure 1a shows a dose dependent decrease in TCF activity upon treatment with aspirin or indomethacin. The eects of these agents on the viability of CRC cells have been studied extensively and concentrations of 1 ± 5 mM aspirin or 100 ± 400 mM indomethacin are now commonly used. Similar concentrations were measured in the serum of patients treated with aspirin and sodium salicylate for chronic in¯ammatory diseases (Goodman et al., 1996) . Within 24 h of treatment, a 5 mM concentration of aspirin reduced TCF activity in SW948 cells to *50% of that in control cells. The same reduction was achieved using 200 mM indomethacin. Both NSAIDs also reduced luciferase expression from a reporter construct containing the TCF-responsive elements in combination with a SV40 minimal promoter (data not shown).
A critical step in TCF activation is its interaction with b-catenin. To determine, whether aspirin and indomethacin confer their inhibitory eect upstream or downstream of b-catenin signaling, we cotransfected a constitutively active b-catenin mutant (amino acid residue deletion Ser45) together with the reporter constructs into SW948 cells. Consistent with previous reports TCF activity increased signi®cantly upon expression of the mutated b-catenin (Figure 1b) . In contrast, both, aspirin and indomethacin reduced the increased TCF activity to almost basic level (Figure 1b) , suggesting that these drugs may inhibit b-catenin itself or downstream components rather than upstream regulators of the b-catenin/TCF pathway.
Since activation of TCF can be modulated by the level of b-catenin which is regulated by degradation, we analysed the total amount of b-catenin in response to aspirin or indomethacin treatment, respectively. As shown by immunoblots (Figure 1c ), neither drug aected the total b-catenin level. Furthermore, no additional bands, representing b-catenin degradation products were observed in lysates of NSAID treated 
Aspirin and indomethacin modulate b-catenin/TCF activity independently of COX-2
To further elucidate the speci®city of aspirin and indomethacin on inhibition of the b-catenin/TCF pathway, we analysed TCF activity in additional CRC cell lines of dierent genetic background. SW480 and SW948 do not express COX-2 (Smith et al., 2000; our own data). Furthermore, SW480, like SW948 harbors a truncating APC mutation, leading to elevated levels of TCF dependent transcriptional activity . The CRC cell lines LoVo and HCT116 are derived from tumors of the microsatellite instability (MSI) phenotype. In addition, LoVo cells express a truncated APC, while HCT116 was shown to contain a TCF-activating mutant form of b-catenin (amino acid deletion Ser45; Rowan et al., 2000; Morin et al., 1997) . As shown in Figure 2 , aspirin and its major metabolite salicylate reduced TCF activity in all four cell lines to basal level, comparable to that, obtained with the TCF-non-responsive reporter (pFOP). Equivalent results were obtained, when the cells were treated with indomethacin. In contrast, dexamethasone, a synthetic anti-in¯ammatory glucocorticoid, which inhibits COX-2 expression at doses of 10 710 to 10 76 M (Goppelt-Struebe et al., 2000) failed to aect TCF activity in either cell line, even at higher concentrations (10 75 M). Together, these ®ndings indicate, that the inhibitory eects of aspirin and indomethacin might not depend on COX-2 activity and appear to be independent from the type of mutation responsible for upregulation of b-catenin/TCF signaling.
Expression of b-catenin/TCF transcriptional targets is inhibited by NSAIDs
The above ®ndings suggest that transcription of bcatenin/TCF-4 regulated genes is suppressed by NSAIDs through a mechanism independent from the b-catenin level. To con®rm the data obtained by the luciferase reporter assays, we analysed the expression of the recently described TCF target cyclin D1 following aspirin or indomethacin treatment. Since Western-blot analysis with antibodies against cyclin D1 or TCF-4 were carried out on whole-cell lysates prepared from synchronized cells treated with the indicated amount of aspirin or indomethacin. The blot was stripped and Western-blotting with an anti-actin antibody was performed to demonstrate equivalent loading of the lines the expression level of cyclin D1 is cell cycle dependent, cells were serum deprived for synchronization prior to NSAID treatment. Semiquantitative RT ± PCR analysis revealed that both aspirin and indomethacin signi®-cantly reduced cyclin D1 mRNA expression in all four CRC cell lines tested (Figure 3a) . At 24 h, treatment with either NSAID was associated with a concentration-dependent decrease in cyclin D1 transcription unlike actin transcription which remained unchanged. Consistent with the mRNA data, cyclin D protein expression decreased in response to both aspirin and indomethacin, as is apparent from Western blot analysis of SW948 and SW480 cells (Figure 3b ). The protein level of TCF-4 was not aected by either drug, excluding the possibility that the NSAIDs mediate their repressive eect by reducing the amount of the transcription factor TCF-4.
Subcellular localization of b-catenin is not affected by NSAID treatment
Current models propose that accumulation of nuclear b-catenin might be responsible for TCF-activation . We therefore considered the possibility that the downregulation of TCF-responsive target gene expression in response to NSAIDs might be caused by changes in the subcellular localization of bcatenin. We determined b-catenin distribution upon NSAID treatment by indirect immuno¯uorescence staining in the CRC cell lines (SW948; SW480; HCT116; LoVo). To match these experiments with our previous target gene expression analysis, all cell lines were synchronized by serum-deprivation prior to addition of the drugs. As illustrated in Figure 4 , no correlation between the subcellular localization of endogenous b-catenin and the observed TCF-4 activity was observed. Untreated SW480 control cells, which exhibit the strongest b-catenin/TCF-4 activity among all four cell lines tested (see Figure 2) , showed a strong Figure  4a ). Neither aspirin nor indomethacin had any eect on the distribution or intensity of b-catenin staining even in the presence of highest concentrations ( Figure  4b,c) . Incubation of SW948 cells with 400 mM indomethacin was highly toxic and resulted in detachment and loss of most of the cells. However, similar to SW480 cells, NSAID treatment of SW948 cells was not associated with changes in the diuse cytoplasmic bcatenin staining pattern in the remaining cells (Figure  4d ± f) . In HCT116 and LoVo cells b-catenin staining was restricted to the lateral cell membrane being most intensive at cell ± cell contacts. Neither aspirin nor indomethacin could alter the distribution of b-catenin in these cells (Figure 4g ± l) .
Binding of the b-catenin/TCF-4 complex to its DNA response element
The inhibitory eect of aspirin and indomethacin on the transcriptional activity of the b-catenin/TCF-4 complex might occur by disruption of the b-catenin/ TCF-4 complex itself or by disruption of its interaction with DNA. We therefore asked whether aspirin or indomethacin can aect binding of the b-catenin/TCF-4 complex to its DNA-response elements. Nuclear extracts derived from drug-treated cells were analysed by electrophoretic mobility shift assays for their ability to interact with 32 P-labeled DNA-fragments containing TCF response elements. Figure 5 shows the result of a representative gel-shift assay to analyse b-catenin/TCF complex formation in untreated and aspirin treated SW948 cells. The observed bands in lanes 1 ± 3 show a pattern similar to that reported previously . When a 32 P-labeled mutated TCF binding region was incubated with the SW948 nuclear extracts, the upper two DNA-protein complexes disappeared, while the amount of free probe increased ( Figure 5 , lanes 4 ± 6). Competition for binding with a 30-fold excess of unlabeled TCF response elements further con®rmed that the upper two bands were speci®c TCF complexes ( Figure 5 , lanes 7 ± 9). Binding of the TCF complexes to their speci®c binding region was not aected by aspirin treatment of SW948 cells ( Figure 5,  lanes 2 and 3) . Similarly, no eect on the TCF complex-DNA interaction was observed in SW480 cells, nor when the cells were treated with increasing amounts of indomethacin (data not shown). Thus, the diminished transcriptional activity of the complexes (Figures 1 and 2) could not be ascribed to a reduction in their binding capacity to responsive DNA elements.
Discussion
Multiple molecular mechanisms seem to be involved in the tumor suppressive eects of NSAIDs. The present study for the ®rst time provides evidence that the bcatenin/TCF-4 signaling pathway is a target of the anti-in¯ammatory drugs aspirin and indomethacin in CRC cells. As indicated by down-regulation of a TCFresponsive reporter gene and of the endogenous TCFregulated target cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 1999) these drugs might antagonise activating signaling mechanisms induced by mutations in components of the pathway. Although several genes were described to be activated by the b-catenin/TCF-4 complex (He et al., 1998 (He et al., , 1999 Mann et al., 1999; Shtutman et al., 1999; Tetsu and McCormick, 1999 ) the consequences of upor down-regulation of the b-catenin/TCF-pathway are not completely understood. Particularly, the connection between the signaling pathway and regulation of apoptosis is unclear. In most CRC cells the pathway is constitutively active at a high level due to defective APC or b-catenin functions. Reconstitution of wildtype APC in CRC cells expressing only mutant endogenous APC down-regulates b-catenin/TCF-activity by degradation of b-catenin and stimulates apoptosis (Morin et al., 1996) . Similarly to wild-type APC, most NSAIDs induce apoptosis in CRC cells (Shi et al., 1995; Ricchi et al., 1997; Chan et al., 1998) . We could now demonstrate that two NSAIDs, aspirin and indomethacin, also down-regulate TCF-activity, thereby reducing transcription of target genes. In contrast, butyrate and sulindac, i.e., both inducers of apoptosis in CRC cells, were recently shown to induce the b-catenin/TCF-pathway (Bordonaro et al., 1999) . Together with our ®ndings, this indicates, that initiation of the apoptotic cascade is not directly attributable to modulation of TCF-activity.
Although the conclusions drawn from the results with dierent NSAIDs are contradictory, they clearly demonstrate that there exists a link between the eects of chemopreventive agents and b-catenin/TCF-4 activity. We therefore focused on b-catenin itself as a major regulator of TCF-responsive transcription for being a target of aspirin and indomethacin action. No reduction of the b-catenin level was observed upon treatment with aspirin or indomethacin, ruling out the possibility, that the agents' interference with the TCFdependent transcription was mediated by regulating the total amount of b-catenin.
Whereas our expression analysis were performed in cell lines, several studies addressed the expression and subcellular localization of b-catenin in response to NSAID treatment in animal models in vivo by immunohistochemical analysis of adenomas. In Min/+-mice, which are predisposed to develop multiple intestinal adenomas due to a germline Apc mutation, the NSAIDs aspirin and sulindac produced a decrease in intracellular b-catenin (Mahmoud et al., 1997 (Mahmoud et al., , 1998 . McEntee et al. (1999) reported a reduced b-catenin level in small intestinal tumors upon 2 and 4 days of sulindac treatment, while in tumors from animals treated for 20 days, b-catenin-levels were not signi®cantly dierent from untreated controls (McEntee et al., 1999) . In addition, high b-catenin staining in colonic tumors of the Min mice was unaected by NSAID treatment. This discrepancy between our in vitro analysis and within some of the in vivo studies concerning b-catenin levels in response to NSAIDs remains to be elucidated. It should be noted that the regulation of the b-catenin level does not necessarily precede the eects on transcriptional activity. Recently, it was shown that with an increasing percentage of apoptosis b-catenin is processed by caspase-3 (Webb et al., 1999) . Therefore, the reduced b-catenin levels observed in vivo rather appears to be a result of apoptosis which follows NSAID-induced down-stream eects. In agreement with our results obtained with four NSAID treated CRC cell lines in vitro, no change in intracellular distribution of b-catenin was involved in vivo.
Although the transcriptional activity of the b-catenin/ TCF-4 complex is down-regulated by aspirin and indomethacin, we did not detect alterations in DNAbinding ability of the complex. Therefore, we suspect that in response to NSAID treatment, this complex is functionally inactive due to post translational modi®ca-tions, i.e. the phosphorylation status of b-catenin and/ or TCF-4. Besides several Ser/Thr-phosphorylation sites involved in degradation of the protein, b-catenin harbors Tyr-phosphorylation sites, which implicate cross-talk with other signaling pathways (Hoschuetzky et al., 1994; Aicher et al., 1997) . Whether Tyrphosphorylation of b-catenin is directly targeted by NSAIDs remains to be determined. Alternatively, cofactors, which are necessary for induction of TCFresponsive transcription could be inactivated in response to NSAIDs. Recently, it was reported that the transcriptional activity of the b-catenin/TCF complex is regulated by binding of the transcriptional cofactor CREB-binding protein (CBP) to b-catenin (Hecht et al., 2000; Takemaru and Moon, 2000) . Furthermore, salicylic acid and aspirin were reported to repress phosphorylation of the cAMP response element binding protein (CREB) (Stevenson et al., 1999) thereby inhibiting CREB-dependent transcription. Together, these ®ndings support the presumption that phosphorylation of b-catenin might be similarly aected by NSAIDs. Finally, co-repressors of the complex might be activated by aspirin and indomethacin.
In summary, we have identi®ed b-catenin/TCFmediated transcription as a target of NSAID action, albeit the mechanism by which aspirin and indomethacin inhibit TCF-activity remains to be established. The present ®ndings might help to explain some features of NSAID-mediated chemoprevention. It is possible, that dierent TCF-responsive downstream genes are regulated by distinct large coactivator/repressor complexes including b-catenin and TCF-4. Future experiments will tell which components of these complexes are aected by NSAIDs and whether selective NSAIDs may play a role in future chemoprevention strategies.
Materials and methods
Cell lines and drugs
Human CRC cell lines (SW480, SW948, LoVo, HCT116) were derived from the tumor collection of the German Cancer Research Center (Tumorbank, DKFZ, Heidelberg). The nonsteroidal anti-in¯ammatory drugs (NSAIDs) aspirin (acetylsalicyclic acid; ASA), sodium salicylate (NA-Sal), indomethacin and dexamethasone were purchased from Sigma, Germany. Fifty mM stock solutions of aspirin and sodium salicylate were prepared in RPMI 1640 and adjusted to pH of 7 ± 7.5 by Tris. Indomethacin was dissolved in acetone to a 10 mM stock solution. In all experiments acetone controls showed no signi®cant eects. Dexamethasone was dissolved in PBS.
Cell culture
Cells were grown in RPMI 1640 medium (Gibco, BRL, Life Technologies, Inc.) supplemented with 10% FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin. All cell lines were grown at 378C in a humidi®ed atmosphere of 5% CO 2 . Cells were routinely subcultured using 0.25% trypsin/EDTA solution. For cell cycle synchronization experiments, cells were serum-starved for 24 h through incubation in RPMI 1640 medium without FCS.
Transfection and reporter gene assays
Transient transfection were performed using SuperFect transfection reagent (QIAGEN, Hilden, Germany) as described previously (Dihlmann et al., 1999) . Brie¯y, 10 6 cells were transfected with 3 mg of the luciferase reporter constructs (pTOP or pFOP, respectively) and 1 mg of pRSVlacZ for normalization. For expression of mutant b-catenin, 1 mg of pCMVD45 was included, as indicated. NSAIDs were added 3 h following transfection. Cells were incubated for 24 h, lysed in Tris-PO 4 -luciferase-buer and collected for assays of luciferase and galactosidase activity, respectively, as described previously (Dihlmann et al., 1999) . The TCFresponsive reporter constructs pTOPFLASH and pFOP-FLASH were kindly provided by H Clevers; University of Utrecht, The Netherlands. Control plasmid pRSV-lacZ was obtained from DKFZ Heidelberg, Germany. The expression plasmid pCMVD45Cat, containing a mutant b-catenin cDNA was kindly provided by KW Kinzler (Johns Hopkins Oncology Center, Baltimore, MD, USA).
Immunofluorescence
Cells were seeded onto tissue culture slides (Roth, Karlsruhe, Germany) to a density of 10 5 cells/cm 2 and grown in RPMI 1640 over night. Following serum-deprivation for 24 h, monolayers were treated for 24 h with aspirin (0, 1, 2, 5, 10 mM) or indomethacin (100, 200, 400 mM), respectively. Cells were ®xed in methanol at 7208C for 8 min followed by 8 min in acetone at 7208C, and washed with PBS. Primary antibody (2.5 mg/ml of anti-b-catenin; Transduction Laboratories) was added in PBS/5% milk powder/0.1% Tween-20 for 1 h at 48C. The slides were washed three times in PBS/ 0.1% Tween-20 before the secondary antibody was added (3 mg/ml of rabbit-anti-mouse-Cy3; Jackson Immuno Research) in PBS for 1 h. Following 3610 min PBS/0.1% Tween-20 washes, slides were mounted in MOWIOL (Calbiochem, Bad Soden, Germany), supplemented with DAPI (25 mg/ml; Sigma, Germany) for nuclear staining.
Immunoblotting
Cells were treated with NSAIDs as indicated in the ®gure legends. Protein extracts were prepared in RIPA buer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl, 0.5% sodium deoxycholate; 0.1% SDS; 0.5% NP-40) supplemented with proteinase inhibitor cocktail (Complete TM EDTA-free; Boeh-ringer Mannheim, Germany) and dissolved in Laemmli sample buer. Twenty micrograms of total protein were fractionated by SDS ± PAGE and electroblotted on nitrocellulose membranes before immunodetection with the indicated antibody was performed. Primary monoclonal antibodies were against b-catenin (0.5 mg/ml; Transduction Laboratories), cyclin D1 (1 mg/ml; Upstate Biotechnology), TCF-4 (4 mg/ml; Upstate Biotechnology), and actin (ICN Biomedicals). Rabbit-anti-mouse-IgG peroxidase (Dako GmbH, Hamburg, Germany) was used as secondary conjugated antibody for visualization of the proteins by ECL (Amersham-Pharmacia, Freiburg, Germany).
RNA-isolation and RT ± PCR
Total RNA was isolated from cells using the method described by Chomczynski et al. (1987) . For cDNA synthesis, 5 mg of total RNA were included in a 20 ml reaction volume by using hexamer primers and SuperScript II Reverse Transcriptase (Gibco ± BRL, Life Technologies) following the manufacturer's instructions. For PCR, 1/20 of the reverse transcription reaction mixture was ampli®ed with 40 cycles for cyclin D1 or 32 cycles for b-actin. The following primer pairs were designed for detection: cyclin D1: CyD.s (5'-CTGCCGTCCATGCGGAAGAT-3') and CyD.as (5'-ATCT-GTGGCACAAGAGGCAAT-3'); b-actin: ûac.s (5'-ATGTT-TGAGACCTTCAACAC-3') and ûac.as (5'-CACGTGACA-CTTCATGATGG-3'). The annealing temperature for ampli®cation of b-actin was 608C, or 508C for cyclin D1. For ampli®cation of the cyclin D1 fragment, 1/50 (v/v) DMSO was included in the reaction mixture. The relative amount of the ampli®ed PCR products was measured densitometrically after separation on a 1% agarose gel using the BIORAD Gel Doc System (BIORAD, MuÈ nchen, Germany).
Gel electrophoretic mobility shift assays
Cells were treated with aspirin at concentrations of 0, 5 or 10 mM, respectively for 24 h. Nuclear extracts were prepared as described by Schreiber et al. (1989) . The 82 bp double stranded TOP-or FOP-oligonucleotides were excised from the pTOPFLASH or pFOPFLASH plasmid, respectively by SalI restriction endonuclease. One hundred ng of each oligonucleotide was endlabeled with 50 mCi of g 32 P-ATP using 10 U of T4-polynucleotide kinase (PNK; New England Biolabs) at 378C for 1 h, and puri®ed with a nucleotide removal kit (QIAGEN, Hilden, Germany). The labeled oligonucleotides were adjusted to 10 000 c.p.m./ml. For competitions, a 30-fold molar excess of unlabeled oligonucleotide was used.
Binding reactions were performed using a BandShift Kit (Amersham Pharmacia, Freiburg, Germany) in binding buer (40 mM Tris-HCL (pH 7.5); 200 mM NaCl; 2 mM DTT; 2.5% glycerol; 0.05% NP-40; 0.25 mg/ml Poly(dIdC); 5 mM MgCl 2 ). The reaction mixtures, each containing 10 mg of nuclear extracts and 2 ml of the 32 P-labeled DNA probe were incubated for 20 min at room temperature, and subsequently separated on a 5% PAA-Gel in TBE-buer (89 mM Trisborate, pH 8.0; 89 mM boric acid, 1 mM EDTA) at 48C.
